RJA
OLMA icon

Raymond James & Associates’s Olema Pharmaceuticals OLMA Stock Holding History

Raymond James & Associates’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-30,000
Closed -$371K – 3914
2023
Q3 		$371K Buy
+30,000
New +$306K ﹤0.01% 3060

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Raymond James & Associates's OLMA Position: Q4 2023 in Review

Raymond James & Associates sold out of Olema Pharmaceuticals (OLMA) in Q4 2023, closing a stake of 30,000 shares — an estimated $371K sold.

Raymond James & Associates first reported a position in OLMA in Q3 2023 and held it in 1 quarter. The position peaked at $371K in Q3 2023. 113 funds tracked by Wall St. Rank hold OLMA as of Q4 2023.

  • Raymond James & Associates reported no remaining Olema Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Raymond James & Associates sold 30,000 Olema Pharmaceuticals shares in Q4 2023, an estimated $371K.
  • Raymond James & Associates first reported a position in Olema Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Raymond James & Associates's Olema Pharmaceuticals position peaked at $371K in Q3 2023.
  • 113 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q4 2023.

Based on Raymond James & Associates's 13F filing for Q4 2023, filed 16 Jan 2024.